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A vaccine to eliminate malaria would need a multi-stage and multi-species composition 
to achieve robust protection, but the lack of knowledge about antigen targets and mech-
anisms of protection precludes the development of fully efficacious malaria vaccines, 
especially for Plasmodium vivax (Pv). Pregnant women constitute a risk population who 
would greatly benefit from a vaccine preventing the adverse events of Plasmodium 
infection during gestation. We hypothesized that functional immune responses against 
putative targets of naturally acquired immunity to malaria and vaccine candidates will 
be associated with protection against malaria infection and/or poor outcomes during 
pregnancy. We measured (i) IgG responses to a large panel of Pv and Plasmodium 
falciparum (Pf) antigens, (ii) the capacity of anti-Pv ligand Duffy binding protein (PvDBP) 
antibodies to inhibit binding to Duffy antigen, and (iii) cellular immune responses to two 
Pv antigens, in a subset of 1,056 pregnant women from Brazil, Colombia, Guatemala, 
India, and Papua New Guinea (PNG). There were significant intraspecies and inter-
species correlations for most antibody responses (e.g., PfMSP119 versus PfAMA1, 
Spearman’s rho =  0.81). Women from PNG and Colombia had the highest levels of 
IgG overall. Submicroscopic infections seemed sufficient to boost antibody responses 
in Guatemala but not antigen-specific cellular responses in PNG. Brazil had the highest 
percentage of Duffy binding inhibition (p-values versus Colombia: 0.040; Guatemala: 
0.047; India: 0.003, and PNG: 0.153) despite having low anti-PvDBP IgG levels. Almost 
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inTrODUcTiOn
According to the World Health Organization, 438,000 people 
died from malaria in 2015 mostly attributed to Plasmodium 
falciparum (Pf) infection in children (1) although increased 
numbers of severe malaria cases caused by Plasmodium vivax 
(Pv) have been reported in recent years (2–6). Naturally acquired 
immunity to clinical malaria develops with age and exposure to 
infections, and it is classically considered to rely on antibodies 
(7) though cellular memory responses to malaria antigens have 
also been implicated in immunity (8). Thus, immune responses 
against all Pv and/or Pf human stages have been reported, i.e., 
sporozoites (9, 10), merozoites (11, 12), asexual intraerythrocytic 
stages (13, 14), and gametocytes (15). Of note, sterile immunity 
is never acquired even in areas of high transmission, with adults 
having asymptomatic infections with low parasitemias (16) often 
only detected by PCR (17).
Despite this natural acquisition of immunity, adult pregnant 
women are more susceptible to the negative consequences of 
malaria infection than non-pregnant adults, and both Pv and Pf 
infections have been associated with poor pregnancy outcomes 
(18, 19). Nevertheless, immune mediators associated with sus-
ceptibility and clinical outcomes of malaria during pregnancy 
are not fully understood, especially for Pv infection. In the 
case of Pf, a parasite variant expressing the VAR2CSA protein 
on the surface of infected erythrocytes, to which primigravidae 
pregnant women are not immune as they have not been exposed 
before pregnancy, may accumulate in the placenta (20). Indeed, 
antibodies to VAR2CSA have been related to protection against 
or exposure to Pf malaria in pregnancy (20, 21), as well as protec-
tion against poor pregnancy outcomes (22, 23).
A Pv ligand for the placenta (similar to VAR2CSA) has not 
been identified thus far, but we recently reported a positive 
association between antibody levels against two Pv VIR proteins 
with 19 and 26% protein homology to VAR2CSA and birth 
weight (BW), respectively (24). Actually, there is controversy 
about whether Pv has cytoadhesive properties at all, although 
we have found placental Pv monoinfections in Papua New 
Guinea (PNG) (25). Pv infects human red blood cells mainly 
through interaction between the Pv ligand Duffy binding protein 
(PvDBP) and its receptor on reticulocytes, the Duffy antigen 
receptor for chemokines (DARC) (26). PvDBP, specifically the 
binding domain referred to as region II (PvDBPII), is a major 
vaccine candidate (27). Naturally acquired and experimentally 
induced antibodies to PvDBPII inhibit parasite invasion in vitro 
(28) and protect against Pv infection in children in a high trans-
mission area of PNG (29) and clinical Pv malaria in adults in a 
low-transmission area in Brazil (BR) (30), supporting PvDBPII 
as a leading vaccine candidate. Additional characterization of 
naturally acquired immune responses to PvDBP and other Pv 
antigens during pregnancy is needed to identify those responses 
that may mediate protection in this condition and guide antigen 
selection for vaccine development.
Experts agree that a vaccine to eliminate malaria would need to 
include antigens from both Pf and Pv parasites (31). Furthermore, 
a multi-stage and multi-strain vaccine inducing both antibody 
and cellular immune responses would likely be required to 
achieve robust protection against malaria in areas of different 
endemicity. Here, we present a comprehensive longitudinal study 
of naturally acquired antibody responses to nine Pv antigens, 
including the only two vaccine candidates in clinical develop-
ment: circumsporozoite protein (PvCSP) and PvDBP (32). In 
addition, functional capacity of anti-PvDPB and T cell responses 
to PvDBP and one merozoite surface protein (PvMSP119) were 
assessed, as well as antibody responses to six Pf antigens. Women 
from five malaria endemic countries in Latin America, Asia, 
and the Pacific where Pv and Pf coexist were enrolled for this 
immune profiling, enabling us to compare responses among areas 
with different malaria transmission characteristics where diverse 
Plasmodium strains circulate. To our knowledge, this is the first 
study of this scope and magnitude conducted in a multi-country 
cohort of women during and after pregnancy.
MaTerials anD MeThODs
study Design and Population
This study was part of the PregVax project (FP7-HEALTH- 
201588, www.pregvax.net), which studied the burden, impact, 
immune responses, and pathophysiology of Pv in pregnancy 
between 2008 and 2012 in five endemic countries: BR, Colombia 
(CO), Guatemala (GT), India (IN), and PNG. Approximately 
2,000 women per country were enrolled at the first visit at the 
antenatal clinic (recruitment) and followed up until delivery. 
all antibodies had a positive association with present infection, and coinfection with the 
other species increased this association. Anti-PvDBP, anti-PfMSP1, and anti-PfAMA1 
IgG levels at recruitment were positively associated with infection at delivery (p-values: 
0.010, 0.003, and 0.023, respectively), suggesting that they are markers of malaria 
exposure. Peripheral blood mononuclear cells from Pv-infected women presented fewer 
CD8+IFN-γ+ T cells and secreted more G-CSF and IL-4 independently of the stimulus 
used in vitro. Functional anti-PvDBP levels at recruitment had a positive association with 
birth weight (difference per doubling antibody levels: 45 g, p-value: 0.046). Thus, nat-
urally acquired binding-inhibitory antibodies to PvDBP might confer protection against 
poor outcomes of Pv malaria in pregnancy.
Keywords: malaria in pregnancy, vivax, falciparum, immunity, antibodies, T cell, cytokines, PvDBP
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In  all  visits, hemoglobin (Hb) levels, Pv and Pf parasitemias 
by blood smear and malaria symptoms were assessed. Giemsa-
stained thick and thin blood slides were read onsite following 
WHO standard quality-controlled procedures, and external 
validation of a subsample of blood slides was done at the Hospital 
Clinic and at the Hospital Sant Joan de Deu, in Barcelona, Spain. 
BW was recorded. Women with a positive smear were treated 
according to national guidelines, except in PNG where blood 
smears could not be read at the moment of the visit for logisti-
cal reasons (only symptomatic women were thus treated after 
confirmation of infection by rapid diagnostic test).
From the PregVax cohort, 10% of women were randomly 
allocated to the “immunology cohort” and were followed up with 
one visit at least 10  weeks after delivery (postpartum group). 
At recruitment, delivery and postpartum visits, a venous blood 
sample (5–10 mL) was collected aseptically in heparinized tubes. 
Submicroscopic Pv and Pf infections were also determined in a 
random subsample by real-time PCR, except for the Indian sam-
ples, where only Pv infection was examined. Additionally, blood 
samples (10 mL) were collected from 39 malaria naïve donors at 
the blood bank in Hospital Clinic (Barcelona, Spain) and used as 
negative controls.
ethics statement
The protocol was approved by the Hospital Clinic Ethics Review 
Committee (CEIC, Barcelona, Spain), the CDC IRB (USA), and 
the national and/or local ethics committees of each site: the 
Universidad del Valle de Guatemala Ethics Review Committee 
(CE-UVG, GT); the Comité Institucional de Revisión de Ética 
Humana, Facultad de Salud, Universidad del Valle de Cauca (Cali, 
CO); the Comissâo Nacional de Ética em Pesquisa (CONEP, BR); 
the Comitê de Ética em Pesquisa da Fundação de Medicina Tropical 
do Amazonas (FMT-AM, Manaus, BR); the Ethics Committee, 
Sardar Patel Medical College and A.G. Hospitals (Bikaner, 
Rajasthan, IN); and the Medical Research Advisory Committee 
in PNG (MRAC 08.02). Written informed consent was obtained 
from all study participants.
Processing of Plasma and Peripheral 
Blood Mononuclear cells (PBMcs)
Plasma was separated by centrifugation and stored at −80°C. 
Blood cells from PNG and Spain were further fractioned in a 
density gradient medium (Histopaque®-1077, Sigma-Aldrich) to 
obtain PBMCs and stored in liquid nitrogen. Samples from GT, 
CO, BR, and PNG were analyzed at ISGlobal (Barcelona, Spain) 
while plasmas from IN were analyzed in Delhi.
recombinant Proteins and synthetic 
Peptides
Unless otherwise specified, recombinant proteins were cloned 
with an Escherichia coli system using genomic DNA from differ-
ent Plasmodium strains as template. Pv200L (amino acid residues 
121–416 of PvMSP1) was amplified from genomic DNA obtained 
from a Colombian Pv-infected patient (33). PvDBP (receptor-
binding domains—RII) was cloned using Pv Sal-I as template (34). 
PvMSP119 (19 kDa C-terminal region, residues 1639–1729) was 
expressed using the Belem strain as template (35) and PfMSP119 
with the 3D7 strain (36). PfAMA1 (N-terminal ectodomain) was 
cloned using genomic DNA from the Pf 3D7 strain (37). PfEBA175 
(the receptor-binding domain—PfF2) was cloned from the Pf 
CAMP strain (38). The Pf A4 strain was used as template for the 
VAR2CSA DBL3X domain (39) and 3D7 strain for the DBL5ε 
(40) and DBL6ε (41) VAR2CSA domains.
PvMSP1-N (fragment 170-675), full-length PvCSP, and full-
length PvMSP5 were expressed with a glutathione S-transferase 
(GST) tag in a cell-free wheat germ system as reported previ-
ously (11). Expressed proteins were purified on GST SpinTrap 
purification columns (GE Healthcare), and eluted proteins were 
dialyzed in phosphate buffered saline (Tube-O-DIALYZER™, 
GBiosciences). GST was also expressed separately for immune-
reactivity control. The production of the PvCSP-N (residues 
20–96), PvCSP-C (residues 301–372), and PvCSP-R (three 
tandem-repetitions of the residues 96–104) peptides has been 
described elsewhere (9). Five PvDBP peptides [VNNTDTNFH -
(R/S)DITFR, LYLKRKLIYDAAVEG, and LIYDAAVEGDLL(L/F)
KL] containing immunogenic epitopes previously published (42) 
were synthesized at >80% purity by Peptide 2.0 (Chantilly, VA, 
USA) for cellular stimulation assays.
Quantification of igg antibodies
Measurement of plasma IgG antibodies was performed by 
multiplex suspension array using the Luminex™ technology, as 
described before (24). Briefly, 1.1–1.4 million MagPlex® mag-
netic-carboxylated microspheres (Luminex Corporation, TX, 
USA) with different spectral signatures were covalently coated 
with 3 µg of each protein/peptide, following the manufacturer’s 
instructions. Protein-coupled beads were quantified in a Guava® 
Flow Cytometer (Millipore) and mixed in equal amounts. A 
unique batch of microspheres was prepared for the whole study, 
including the samples analyzed in IN. Approximately 1,000 beads 
per analyte were incubated with each plasma (1:100 dilution) in 
duplicates, and subsequently with antihuman IgG-biotin (Sigma-
Aldrich), followed by streptavidin-conjugated R-PE (Fluka, 
Madrid, Spain). Beads were acquired on the BioPlex100 system 
(Bio-Rad, Hercules, CA, USA), and results were expressed as 
median fluorescence intensity (MFI) of duplicates. Value against 
GST alone was subtracted from correspondent proteins. Raw 
GST data have been previously published (24). Cross-reactivity 
was ruled out in a pilot study analyzing a subset of plasmas in sin-
gleplex and multiplex (not shown). Samples in IN were analyzed 
with identical protocols and instruments.
Detection of PvDBP-Binding inhibitory 
antibodies
A functional assay was carried out to study the capacity of 
anti-PvDBP antibodies to inhibit the binding of this protein to 
its receptor DARC, as previously described (43). Only plasma 
samples from responder women (anti-PvDBP MFI values above 
the mean + 3 SD of Spanish naïve controls) at recruitment were 
included in the functional assays. Ten microliters of plasma from 
each donor were preincubated with 0.01 µg/mL of PvDBP for 1 h 
at RT before adding to Bioplex plates containing 1,000 Luminex 
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beads pre-coupled to DARC-Fc (N-terminal extracellular 60 
amino acids of DARC fused to Fc region of human IgG). Bound 
PvDBP was detected with anti-PvDBP, followed by anti-human 
IgG-biotin and streptavidin-conjugated R-PE. A standard curve 
using increasing amount of PvDBP was prepared to establish 
concentration of PvDBP bound to DARC-Fc. Percent inhibition 
was calculated as % Inhibition =  (1 − observed PvDBP conc./
expected PvDBP conc.) × 100.
cellular stimulation assays
Except where indicated, all reagents were purchased from BD 
Biosciences, and all antibodies were monoclonal. PBMCs were 
thawed and rested for 10–12  h. Only samples with viability 
>70% (Guava ViaCount Reagent, Millipore) were used for 
assays. Half a million cells per well were resuspended in RPMI-
1640 medium plus 10% fetal bovine serum (culture medium) 
and incubated in the presence of a pool containing the five 
PvDBP peptides (5  µg/mL) or PvMSP119 (10  µg/mL). Culture 
medium was used as negative control. Anti-CD3 stimulation 
was the positive control (24). After 12 h, an aliquot of 30 µL of 
culture medium supernatant was collected to measure secreted 
cytokines and replaced with media containing GolgiPlug™ for 
an additional (4 h) incubation. PBMCs were stained with LIVE/
DEAD® Fixable Violet Dead (Life Technologies), anti-CD14 
Pacific Blue (clone M5E2), anti-CD19 Horizon™ V450 (clone 
HIB19), anti-CD4 allophycocyanin (clone RPA-T4), and anti-
CD8 Peridinin Chlorophyll Protein Complex (PerCP, clone 
SK1). After washing, cells were fixed and permeabilized with 
Cytofix/Cytoperm™ and incubated with anti-CD3 phycoeryth-
rin (PE)-Cy™7 (clone SK7), anti-interferon (IFN)-γ PE (clone 
25723.11), and anti-CD69 fluorescein isothiocyanate (clone 
L78). Cells were acquired in an LSRFortessa flow cytometer, 
and data were analyzed by FlowJo (FlowJo LLC, OR, USA). The 
gating strategy was developed as previously (24). Supernatants 
were frozen at −80°C until Luminex analysis with the Cytokine 
Magnetic 30-Plex Panel (Invitrogen), according to the manufac-
turer’s instructions.
Plasmodium spp. Detection by Pcr
Samples from BR, CO, GT, and half samples from PNG were 
analyzed at the Istituto Superiore di Sanità (Rome, Italy), as 
described (44). Positivity for each species was established as a 
cycle threshold <45, according to negative controls. Pv diagnosis 
for IN samples was performed in Delhi following Rome’s protocol 
adapted for the instrument sensitivity (third step amplification 
72°C for 25 s instead of 72°C for 5 s). Approximately half of PNG 
samples were analyzed for submicroscopic infections in Madang, 
following a similar protocol to Rome’s (45), except that positivity 
for each species was established as cycle threshold <40, according 
to negative controls. DNA was extracted from whole blood-spot 
samples on filter paper.
Definitions and statistical Methods
Any Plasmodium infection was defined as a positive smear and/or 
positive PCR. A positive antibody response (responder) was con-
sidered as MFI values above the mean + 3 SD of Spanish controls. 
To evaluate the differences in antibody levels among countries, a 
one-way ANOVA test was used followed by Bonferroni pairwise 
correction. To study the association between antibody levels and 
pregnancy variables, univariate (only adjusted for country of 
origin) and multivariate linear regression models were estimated 
with the following variables: country, age, gestational age, gravid-
ity (number of previous gestations), and Pv or Pf infection during 
pregnancy (considering past or present infections but not future–
delivery—infections). The correlation between IgG responses to 
different antigens was evaluated with the Spearman’s rank test. 
The association between IgG levels at recruitment and malaria 
infections at delivery was evaluated with logistic regression mod-
els. The association between antibody responses and pregnancy 
outcomes, i.e., Hb levels at delivery and BW, was analyzed using 
univariate and multivariate linear regression models, adjusted 
by country, Hb at recruitment, gestational age at recruitment, 
age, gravidity, and past or present Plasmodium infection during 
pregnancy. For the cellular and cytokine analyses, deviation from 
normality was tested using the skewness and kurtosis test. Because 
none of the variables except IL-13 presented a normal distribu-
tion, data were presented as medians, and comparisons between 
groups were done using the Mann–Whitney U test. The cytokine 
multiple comparisons were adjusted using the Bonferroni test. 
Cytokine/chemokine production in culture supernatants of 
unstimulated samples (medium) was not subtracted from the 
stimulated samples but shown side by side as it is possibly biologi-
cally relevant. Significance was defined at p < 0.05. Analyses and 
graphs were performed using Stata/SE 10.1 (College Station, TX, 
USA).
resUlTs
study Population
In total, 1,491 peripheral blood samples (794 at recruitment—first 
antenatal visit, 529 at delivery, and 168 postpartum) corresponding 
to 1,056 women were analyzed for IgG antibody responses against 
both Pv (six recombinant proteins and three peptides) and Pf (six 
recombinant proteins). Unfortunately many of our samples were 
not matched due to late attendance to antenatal clinics or low 
follow-up rate. The baseline study population characteristics and 
infection rates by country have been published previously (24).
For cellular assays, 46 samples (any gestational age including 
delivery, 18 Pv PCR negative, 28 Pv PCR positive) from the PNG 
pregnant cohort were included in the analyses. When cell counts 
were limited, stimulation with PvMSP119 was the last priority, 
resulting in a lower sample size (12 Pv PCR negative and 15 Pv 
PCR positive).
antibody responses to Pv Preerythrocytic 
antigens
IgG MFI values against the four Pv preerythrocytic antigens 
differed among countries at all timepoints (one-way ANOVA 
p < 0.05). Overall, PNG had the highest levels of all anti-PvCSP 
antibodies at recruitment and delivery followed by CO; at 
postpartum CO had similar or higher levels (Figure 1). PvCSP 
protein was more reactive (seropositivity and/or MFI levels) 
than the three PvCSP peptides in PNG and GT, but they were 
FigUre 1 | antibody responses against Plasmodium vivax preerythrocytic stage antigens. Human IgG antibodies against P. vivax preerythrocytic stage 
antigens were detected by Luminex in peripheral plasma at recruitment (a), delivery (B), and postpartum (c). Antibody responses are represented as median 
fluorescence intensity (MFI). Reactivity (MFI) against glutathione S-transferase was subtracted from MFI values of PvCSP. Median (white line), and 25th and 75th 
percentiles (lower and upper hinge, respectively) are represented in the box. Outside values are not displayed in the graphs. Numbers below boxes represent 
percentage of positive responses, calculated as number of plasmas with MFI value above mean + 3 SD of negative controls from Spain. Cutoff for India samples 
was calculated with negative samples analyzed at this site and therefore differed from cutoff used for the other sites. p-Values correspond to one-way ANOVA plus 
Bonferroni pairwise correction. *p < 0.05, **p < 0.01, ***p < 0.001. Only displayed differences versus Papua New Guinea (PNG). Sample size: recruitment, Brazil: 
133, Colombia: 217, Guatemala: 173, India: 134, PNG: 137; delivery, Brazil: 75, Colombia: 117, Guatemala: 105, India: 98, PNG: 134; postpartum, Brazil: 38, 
Colombia: 10, Guatemala: 60, India: 5, PNG: 55.
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FigUre 2 | continued
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FigUre 3 | antibody responses against Plasmodium falciparum merozoite and erythrocytic stage antigens. Human IgG antibodies against P. falciparum 
blood stage antigens were detected by Luminex in peripheral plasma at recruitment (a), delivery (B), and postpartum (c). Antibody response representation and 
sample size are as in Figure 1 (see Figure 1 legend). p-Values correspond to one-way ANOVA plus Bonferroni pairwise correction. ***p < 0.001
FigUre 2 | continued  
antibody responses against Plasmodium vivax merozoite stage antigens. Human IgG antibodies against P. vivax merozoite stage antigens were detected by 
Luminex in peripheral plasma at recruitment (a), delivery (B), and postpartum (c). Antibody response representation and sample size are as in Figure 1 (see 
Figure 1 legend). (D) Percentage of Pv ligand Duffy binding protein (PvDBP)-binding inhibition at recruitment. Sample size: Brazil: 18, Colombia: 71, Guatemala: 52, 
India: 34, and Papua New Guinea (PNG): 47. p-Values correspond to one-way ANOVA plus Bonferroni pairwise correction. *p < 0.05, **p < 0.01, ***p < 0.001
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recognized at similar levels in BR, CO, and IN. PvCSP-N was 
the most reactive of the three peptides in all countries and at all 
timepoints, except CO and BR at postpartum, where PvCSP-R 
was more seroprevalent (Figure  1). We also observed higher 
anti-PvCSP peptide levels at postpartum compared to recruit-
ment and delivery, but this was not found for anti-PvCSP 
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protein levels (Table S1 in Supplementary Material). In general 
and as expected, MFI and seroprevalence values for anti-PvCSP 
antibodies were low compared to merozoite antigens (Figure 2).
antibody responses to Pv Merozoite 
stage antigens
Similar to anti-PvCSP responses, prevalence of anti-Pv merozoite 
antibodies differed among countries at all timepoints (one-way 
ANOVA p < 0.05), and PNG presented the highest magnitudes 
and prevalence at recruitment and delivery followed by CO 
(Figures  2A,B). In contrast to anti-PvCSP responses, women 
from GT presented remarkable anti-merozoite levels at all time-
points in spite of lower prevalence of patent malaria infections. 
Reactivity of each antigen varied across countries and timepoints; 
for instance antibody values for Pv200L and PvMSP1-N were 
lower than for PvDBP in BR, CO, and IN, but similar and higher 
in GT and PNG, respectively. The levels of PvDBP and PvMSP119 
antibodies in CO at postpartum were very high compared to 
the rest of countries (Figure 2C). We did not find differences in 
antibody levels between timepoints.
We also measured binding-inhibition percentage to Duffy 
antigen in the plasma of positive PvDBP responders at recruit-
ment. Although BR had the lowest number of responders, the 
anti-PvDBP antibodies on those responders had the highest 
amount of inhibitory activity (one-way ANOVA p  =  0.01, 
Figure 2D), with 8/18 individuals having more than 50% inhibi-
tory activity.
antibody responses to Pf Blood stage 
antigens
Differential Pf antibody responses were observed between coun-
tries at all timepoints (one-way ANOVA p <  0.05), and PNG 
presented the highest magnitudes except for PfMSP119, PfDBL3x, 
PfDBL5ε, and PfDBL6ε at postpartum that were similar in CO 
(Figure  3). CO presented the second highest anti-Pf antibody 
levels, while antibodies were almost absent in BR and IN. Of 
note, GT presented remarkable anti-Pf responses, similar in some 
cases to CO, despite low prevalence of Pf infection in our cohort. 
PfAMA1 antibodies had the highest MFI values (not so for 
seroprevalence) in all cases, and anti-PfAMA1 IgG levels in PNG 
were higher than any Pv antigen-specific antibodies (Figure 3). 
When we compared magnitude of antibody responses between 
timepoints, we found lower anti-PfMSP119 at delivery and higher 
anti-PfDBL3x levels at postpartum compared to recruitment 
(Table S1 in Supplementary Material).
correlation of antibody levels
To study the possibility of cross-reactivity, we analyzed the cor-
relation between antibody levels (Table  1). There was a good 
correlation between the levels of antibodies of the same group 
(preerythrocytic, merozoite, and PfEMP1 family) except for 
PvCSP protein and peptides. The highest intraspecies correla-
tion was observed between anti-PfMSP119 and anti-PfAMA1 
levels (Table 1). With regards to interspecies correlation, this was 
relatively high between Pv and Pf anti-merozoite antibody levels 
(Spearman’s rho ≥ 0.45 depending on the antibody, p < 0.0001 
FigUre 4 | correlation of antibody responses. Scatter plots show the distribution of values of mean fluorescence intensity in logarithmic scale for anti-PfDBL3x 
and anti-PvCSP-N, -R, and -C antibody levels. Samples corresponded to pregnant women of all countries at recruitment (n = 794).
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for them all, Table 1). Interestingly, we found a high correlation 
between levels of antibodies against the three PvCSP peptides and 
VAR2CSA domains, especially PfDBL3x (Spearman’s rho ≥ 0.64, 
p < 0.0001, Table 1; Figure 4). The percentage of PvDBP func-
tional antibodies correlated poorly with the levels of all antibod-
ies, except for anti-PvDBP, anti-PvMSP1-N, and anti-PvMSP5 
(all p < 0.0001).
association of antibody levels with 
Pregnancy Variables and infection
Next, we assessed how different pregnancy variables affected 
the levels of antibodies. As expected, country of origin was 
significantly associated with all antibodies, both at recruit-
ment and at delivery (not shown). In the adjusted regression, 
PfMSP119 IgG responses had a positive association with age 
at delivery (proportional differences per 1  year increase in 
age = 1.04, 95% CI = 1.00–1.08, p = 0.042). PvMSP1-N anti-
body levels had a positive association with gravidity [propor-
tional difference in antibody levels per belonging to category: 
(0 previous gestations) = 1; (1–3 previous gestations) = 2.06, 
95% CI =  1.24–3.42; (4+ previous gestations) =  2.01, 95% 
CI = 0.87–4.63; p = 0.020] and with gestational age (propor-
tional differences per 1 week increase in gestational age = 1.05, 
95% CI = 1.02–1.08, p = 0.002) at recruitment. Most antibod-
ies presented a positive association with current Plasmodium 
infection (infection status at time of sample collection), which 
was more prominent at recruitment than at delivery (Tables 2 
and 3, data at delivery not shown). Of note, women with Pf 
and Pv coinfection had significantly more anti-PvMSP119, anti-
Pv200L, and anti-PvDBP (borderline difference for PvDBP) 
antibodies than women with Pv monoinfections (Table  2). 
Similarly, coinfected women had more anti-Pf antibodies 
than women with Pf infection alone in most cases (Table 3). 
However, sample size for coinfections was small, and these 
results should be considered cautiously.
association between antibody levels, 
Future Malaria and Delivery Outcomes
We also analyzed the association between the levels of antibody 
levels at recruitment in uninfected women and infection rates 
at delivery (future infection). Anti-PvDBP levels were positively 
associated with future Pv infection, and anti-PfMSP119 and 
anti-PfAMA1 levels were positively associated with future 
Pf infection (Table  4). In addition, antibody levels against 
PfMSP119 and PfAMA1 were associated with future Pv infection 
(Table 4).
Subsequently, we assessed the association between antibody 
levels at recruitment and delivery outcomes (Hb and BW). Anti-
PvCSP-C and anti-PvCSP IgG levels had a positive and negative 
association, respectively, with Hb levels at delivery, but these 
associations were not maintained in the adjusted analysis. Anti-
PvCSP-C and anti-PfDBL3x antibody levels, and the percentage 
of inhibitory anti-PvDBP antibodies, were positively associated 
with BW (Table 5), but only the last two variables maintained the 
association in the adjusted analysis.
antigen-specific cellular immune 
responses to Pv antigens
We compared the cellular immune responses to PvDBP peptides 
and PvMSP119 between Pv infected and uninfected pregnant 
women in the PNG cohort. PBMCs from women with a concur-
rent Pv infection had less CD8+IFN-γ+ cells than uninfected 
women independently of whether we cultured the cells in the 
presence of the antigens or medium alone (Figure 5). The differ-
ences for the CD4+IFN-γ+ population were not statistically sig-
nificant (medium p = 0.085, DBP p = 0.083, PvMSP119 p = 0.064, 
Figure 5). No differences between infected and uninfected groups 
were found when we stimulated with anti-CD3 (24) or when we 
measured CD69+ T cells (not shown). In the supernatants of the 
PBMCs cultured with either PvDBP peptides (Table 6; Figure 5) 
or medium alone (24), we found significantly more G-CSF and 
IL-4 in the infected than in the uninfected group. Specifically 
in response to PvDBP peptides, PBMCs from infected women 
secreted significantly less IL-17 than those from uninfected 
women (Table 6; Figure 5). However, none of these differences 
remained significant after adjusting for multiple comparisons, 
and these results should be interpreted with caution.
DiscUssiOn
Here, we present data on immune responses to a large panel of 
Plasmodium antigens in pregnant women from five countries with 
TaBle 3 | association of antibody levels against P. falciparum at 
recruitment and infection status at recruitment.
recruitment
adj eff 95% ci p
PfMSP119 Pv−/Pf− 1.00 <0.001
Pv+/Pf− 1.49 0.93; 2.38
Pv−/Pf+ 2.34 1.50; 3.66
Pv+/Pf+ 6.06 1.67; 22.03
PfAMA1 Pv−/Pf− 1.00 <0.001
Pv+/Pf− 1.55 1.02; 2.33
Pv−/Pf+ 1.87 1.27; 2.77
Pv+/Pf+ 5.98 1.93; 18.52
PfEBA175 Pv−/Pf− 1.00 0.003
Pv+/Pf− 1.18 0.85; 1.63
Pv−/Pf+ 1.48 1.09; 2.02
Pv+/Pf+ 3.45 1.41; 8.44
PfDBL3x Pv−/Pf− 1.00 <0.001
Pv+/Pf− 1.34 1.01; 1.78
Pv−/Pf+ 1.56 1.19; 2.04
Pv+/Pf+ 2.54 1.16; 5.55
PfDBL5ε Pv−/Pf− 1.00 <0.001
Pv+/Pf− 1.61 1.15; 2.27
Pv−/Pf+ 1.61 1.17; 2.23
Pv+/Pf+ 3.07 1.20; 7.86
PfDBL6ε Pv−/Pf− 1.00 <0.001
Pv+/Pf− 1.35 1.02; 1.80
Pv−/Pf+ 1.76 1.35; 2.31
Pv+/Pf+ 1.48 0.68; 3.23
Adjusted effect (Adj eff) represents the fold increase in antibody levels [median 
fluorescence intensity (MFI)] when comparing each infection group with the uninfected 
(Pv−/Pf−) one, after adjusting for the following variables: country of origin, age, 
gravidity (number of previous gestations), and gestational age. Pv: Plasmodium vivax. 
Pf: Plasmodium falciparum. N: Pv−/Pf− N = 672; Pv+/Pf− N = 52; Pv−/Pf+ N = 33; 
Pv+/Pf+ N = 5. Highlighted in bold if p-value < 0.05.
TaBle 2 | association of antibody levels against P. vivax at recruitment 
and infection status at recruitment.
recruitment
adj eff 95% ci p
PvCSP Pv−/Pf− 1.00 0.039
Pv+/Pf− 2.26 1.18; 4.33
Pv−/Pf+ 0.65 0.35; 1.22
Pv+/Pf+ 1.62 0.27; 9.65
PvCSP-N Pv−/Pf− 1.00 0.130
Pv+/Pf− 1.32 1.02; 1.72
Pv−/Pf+ 1.10 0.85; 1.41
Pv+/Pf+ 1.46 0.71; 3.00
PvCSP-C Pv−/Pf− 1.00 0.051
Pv+/Pf− 1.32 1.05; 1.66
Pv−/Pf+ 0.97 0.78; 1.21
Pv+/Pf+ 1.62 0.86; 3.04
PvCSP-R Pv−/Pf− 1.00 0.030
Pv+/Pf− 1.43 1.12; 1.81
Pv−/Pf+ 0.99 0.79; 1.24
Pv+/Pf+ 1.27 0.66; 2.46
Pv ligand Duffy binding protein Pv−/Pf− 1.00 <0.001
Pv+/Pf− 2.42 1.65; 3.57
Pv−/Pf+ 1.31 0.91; 1.90
Pv+/Pf+ 2.83 0.98; 8.21
PvMSP119 Pv−/Pf− 1.00 <0.001
Pv+/Pf− 2.67 1.60; 4.45
Pv−/Pf+ 1.25 0.77; 2.03
Pv+/Pf+ 15.67 3.84; 63.89
Pv200L Pv−/Pf− 1.00 <0.001
Pv+/Pf− 2.40 1.57; 3.66
Pv−/Pf+ 1.35 0.90; 2.02
Pv+/Pf+ 4.15 1.29; 13.35
PvMSP1-N Pv−/Pf− 1.00 0.072
Pv+/Pf− 2.60 1.09; 6.20
Pv−/Pf+ 1.04 0.46; 2.37
Pv+/Pf+ 6.94 0.65; 74.24
PvMSP5 Pv−/Pf− 1.00 0.091
Pv+/Pf− 2.40 1.02; 5.65
Pv−/Pf+ 0.59 0.26; 1.31
Pv+/Pf+ 2.53 0.25; 26.11
Adjusted effect (Adj eff) represents the fold increase in antibody levels [median 
fluorescence intensity (MFI)] per belonging to each category, after adjusting for the 
following variables: country of origin, age, gravidity (number of previous gestations), 
and gestational age. Pv: Plasmodium vivax. Pf: Plasmodium falciparum. N: Pv−/Pf− 
N = 672; Pv+/Pf− N = 52; Pv−/Pf+ N = 33; Pv+/Pf+ N = 5. Highlighted in bold if  
p-value < 0.05.
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different malaria transmission patterns followed up since recruit-
ment at first antenatal clinic visit until postpartum. Responses to 
each antigen were very variable but, in general, antibody levels 
were quite consistent with recent patterns of malaria transmission 
intensity in the areas. Furthermore, we show evidence of impact 
of submicroscopic infections and cross-species reactivity on 
antibody responses, and positive effects of functional antibodies 
on delivery outcomes.
Women from PNG had the highest antibody responses for all 
antigens at recruitment and delivery, and this difference was more 
dramatic for anti-Pf responses, in agreement with the highest Pf 
prevalence. PNG is also the country with the highest endemicity 
for Pv, even if at the time of the study there was a transient drop in 
malaria transmission intensity there. Nevertheless, at postpartum, 
women from CO had higher IgG levels than PNG for most anti-
Pv antigens, which can be explained by a very high prevalence 
of Pv infections (40%) in our cohort in CO at postpartum (24), 
which was not observed to that extent at recruitment or delivery. 
BR and IN presented intermediate and low anti-Pv IgG levels, 
respectively, and very low anti-Pf responses, in agreement with 
their infection prevalence rates.
We observed different sera reactivity for full-length PvCSP 
and its peptides between PNG and the other countries. This may 
be explained by different distribution of the two genetic variants 
of the PvCSP repeat region in the different malaria regions world-
wide. The full-length protein was a chimeric one with the two 
variants (VK247 and VK210), whereas the R peptide tested was 
based on the VK210. In previous studies in sera from Colombia 
subjects, it was showed a higher recognition of VK210 (46) than 
of VK247, which would explain the high reactivity of the peptide 
R at postpartum in CO. Of note, although anti-PvDBP levels were 
not high in BR, they showed the highest percentage of binding 
inhibition to Duffy antigen. Differences in the level of inhibition 
TaBle 5 | association of antibody levels at recruitment with delivery outcomes.
hemoglobin (g/dl) BW (g)
crude adjusted crude adjusted
Diff 95% ci p Diff 95% ci p Diff 95% ci p Diff 95% ci p
PvCSP-N 0.0 −0.1; 0.2 0.640 0.0 −0.1; 0.2 0.639 6 −34; 46 0.771 10 −31; 51 0.634
PvCSP-C 0.2 0.0; 0.4 0.045 0.1 −0.1; 0.3 0.292 47 0.6; 93 0.048 37 −10; 84 0.121
PvCSP-R 0.1 −0.1; 0.2 0.361 0.0 −0.2; 0.2 0.966 28 −16; 72 0.209 27 −17; 71 0.230
PvCSP −0.1 −0.1; −0.0 0.046 −0.1 −0.1; 0.0 0.118 −2 −19; 14 0.796 1 −16; 17 0.937
PvDBP 0.0 −0.1; 0.1 0.521 0.1 −0.1; 0.2 0.368 4 −22; 31 0.740 −9 −37; 20 0.544
PvMSP119 0.0 −0.1; 0.0 0.322 0.0 −0.1; 0.0 0.531 13 −7; 33 0.201 9 −12; 30 0.406
Pv200L 0.0 −0.1; 0.1 0.544 0.0 −0.1; 0.1 0.888 −3 −27; 22 0.825 2 −23; 26 0.896
PvMSP1-N 0.0 −0.1; 0.0 0.627 0.0 −0.0; 0.0 0.800 7 −5; 18 0.267 −3 −16; 9 0.608
PvMSP5 0.0 −0.0; 0.0 0.951 0.0 −0.0; 0.0 0.973 2 −11; 14 0.795 −10 −23; 3 0.119
PvDBP-Inh 0.0 −0.1; 0.1 0.959 0.0 −0.1; 0.2 0.626 49 8; 90 0.020 45 1; 89 0.046
PfMSP119 0.0 −0.1; 0.1 0.845 0.1 −0.0; 0.1 0.296 8 −14; 30 0.470 12 −10; 35 0.285
PfAMA1 0.0 −0.1; 0.1 0.876 0.1 −0.1; 0.1 0.378 10 −16; 36 0.447 18 −10; 45 0.205
PfEBA175 0.0 −0.1; 0.1 0.816 0.0 −0.1; 0.1 0.947 2 −31; 35 0.898 3 −32; 37 0.883
PfDBL3x 0.1 −0.0; 0.2 0.169 0.1 −0.0; 0.3 0.101 63 26; 101 0.001 60 22; 99 0.003
PfDBL5ε 0.0 −0.1; 0.1 0.750 0.1 −0.1; 0.2 0.320 24 −9; 56 0.157 17 −16; 49 0.323
PfDBL6ε 0.0 −0.1; 0.2 0.626 0.1 −0.0; 0.2 0.168 21 −14; 57 0.243 18 −18; 54 0.325
Diff: difference in hemoglobin (Hb) at delivery (g/dL) or birth weight (BW, expressed in grams) per doubling antibody levels at recruitment. Highlighted in bold if p < 0.05. Regression 
analyses were performed adjusting by site, gestational age at recruitment (weeks), age (years), parity, Hb levels at recruitment (for Hb analysis at delivery), and Plasmodium vivax and 
Plasmodium falciparum infection. N = 382 [Pv ligand Duffy binding protein (PvDBP)-inhibition = 106].
TaBle 4 | association of antibody levels at recruitment and infection status at delivery (future infection).
Future Pv infection Future Pf infection
crude (adjusted by site) adjusted crude (adjusted by site) adjusted
Or 95% ci p Or 95% ci p Or 95% ci p Or 95% ci p
PvCSP 1.00 0.84; 1.20 0.998 0.97 0.79; 1.18 0.744 1.29 0.99; 1.69 0.058 1.30 0.99; 1.70 0.056
PvCSP-N 1.46 0.94; 2.27 0.092 1.57 0.98; 2.51 0.058 1.31 0.75; 2.30 0.337 1.34 0.76; 2.35 0.309
PvCSP-C 1.05 0.57; 1.95 0.877 1.04 0.53; 2.04 0.902 1.10 0.49; 2.44 0.822 1.13 0.48; 2.64 0.778
PvCSP-R 1.09 0.57; 2.06 0.801 1.09 0.55; 2.16 0.800 0.85 0.36; 1.99 0.703 0.85 0.35; 2.09 0.725
PvDBP 1.59 1.13; 2.24 0.008 1.64 1.13; 2.38 0.010 1.00 0.61; 1.64 0.996 1.02 0.63; 1.67 0.925
PvMSP119 1.09 0.81; 1.47 0.577 1.11 0.81; 1.54 0.511 1.13 0.76; 1.67 0.555 1.13 0.76; 1.68 0.534
Pv200L 0.92 0.69; 1.24 0.602 0.93 0.68; 1.28 0.660 1.27 0.81; 2.00 0.296 1.30 0.82; 2.06 0.259
PvMSP1-N 1.13 0.94; 1.35 0.199 1.19 0.96; 1.46 0.110 1.06 0.84; 1.33 0.642 1.07 0.85; 1.35 0.558
PvMSP5 1.02 0.84; 1.23 0.837 1.04 0.84; 1.27 0.740 1.17 0.86; 1.58 0.314 1.16 0.84; 1.58 0.368
PvDBP-inhibition 1.24 0.84; 1.84 0.272 1.38 0.88; 2.17 0.162 0.99 0.48; 2.02 0.973 0.75 0.40; 1.39 0.359
PfMSP119 1.41 1.05; 1.90 0.024 1.39 1.02; 1.90 0.039 2.21 1.28; 3.84 0.005 2.43 1.36; 4.34 0.003
PfAMA1 1.49 0.99; 2.23 0.054 1.65 1.06; 2.56 0.027 2.14 1.12; 4.09 0.021 2.10 1.11; 3.98 0.023
PfEBA175 1.36 0.91; 2.02 0.134 1.31 0.86; 1.99 0.208 1.00 0.57; 1.76 0.987 1.02 0.59; 1.79 0.932
PfDBL3x 1.24 0.80; 1.92 0.338 1.29 0.80; 2.10 0.293 1.09 0.65; 1.83 0.736 1.09 0.64; 1.85 0.754
PfDBL5ε 1.27 0.88; 1.84 0.208 1.24 0.83; 1.87 0.295 1.36 0.88; 2.10 0.162 1.38 0.89; 2.12 0.148
PfDBL6ε 1.18 0.74; 1.86 0.487 1.34 0.81; 2.23 0.255 0.95 0.55; 1.64 0.857 0.94 0.54; 1.62 0.815
Crude (adjusted only by site) and adjusted logistic regression models were estimated to calculate the odds ratio (OR) of having Plasmodium vivax (Pv) or Plasmodium falciparum 
(Pf) infection at delivery per doubling antibody levels (MFI) at recruitment. Variables in the adjusted analyses are country of origin, age, gravidity (number of previous gestations), and 
gestational age. Only uninfected women at recruitment were included in the analysis. N: crude analysis = 456 [Pv ligand Duffy binding protein (PvDBP)-inhibition = 121]; adjusted 
analysis = 445 (PvDBP-inhibition = 118). Highlighted in bold if p-value < 0.05.
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have been associated to the Duffy antigen phenotype (47, 48) but 
whether women from BR express the protective Duffy phenotype 
in a higher proportion than women from the other countries 
could not be assessed in this study. Regardless, our results support 
the previous finding that efficacy of a PvDBP-based vaccine may 
differ among populations (47).
Antibody patterns in GT were very interesting. There were 
remarkable anti-Pv humoral responses despite very low Pv-
infection prevalence by microscopy but in agreement with the 
high prevalence of submicroscopic infections in the country, as 
shown in this cohort (24) and in a different study (49). Plasma 
antibodies are a combined result of those secreted by long-lived 
FigUre 5 | In vitro production of cytokines by peripheral blood mononuclear cell (PBMc) in response to antigen stimulation. (a) Percentage of IFN-γ+ 
cells on CD4+ and CD8+ T cells as indicated by boxplot with whiskers or (B) cytokine concentration in supernatant after incubation of PBMCs with medium, Pv 
ligand Duffy binding protein (PvDBP) peptides, PvMSP119, or anti-CD3 mAb were analyzed and compared between Plasmodium vivax infected (I, N = 28 except 
PvMSP119 where N = 15) or uninfected women (U, N = 18 except PvMSP119 where N = 12). Median (white line), and 25th and 75th percentiles (lower and upper 
hinge, respectively) are represented in the boxes. Outside values were excluded in panel (a). *p < 0.05, Mann–Whitney test.
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plasma B cells (from previous exposures) and those boosted by 
memory B cells in each new infection. On the one hand, although 
antibody titers are generally perceived to decline rapidly in the 
absence of reinfection, half-lives of 4  years for PvAMA1 have 
been reported in pregnant women (12). On the other hand, our 
results also suggest that submicroscopic infections are enough 
to boost Plasmodium-specific antibody responses, emphasizing 
the importance of analyzing submicroscopic infections in cohort 
studies, especially in adult populations and/or low-transmission 
areas.
Surprisingly, we found more than 60% of responders for 
PfMSP119 and PfAMA1 in GT, despite low Pf-infection preva-
lence both by microscopy and PCR. Historic exposure surely 
accounts for this finding, as half-lives of 4–10 years for PfMSP119 
and PfAMA1 have been reported (12, 50). Nevertheless, we also 
found that coinfected individuals had more anti-Pf antibodies 
than individuals with Pf-monoinfection, thus it would be possible 
that Pv infections boosted anti-Pf responses in GT. Both MSP1 
and AMA1 have orthologs in Pv and Pf, and we found a high level 
of correlation between Pv and Pf anti-merozoite levels. However, 
although species cross-reactivity has been described for other 
antigens such as MSP5 (51) and CLAG (52), it was not observed 
with MSP1 (53), and it has not been described for AMA1. An 
alternative explanation could be a Pf-specific B cell bystander 
activation by the pro-inflammatory Pv infection (54).
IgGs against PvCSP peptides and PfDBL3x were higher 
at postpartum compared to recruitment and delivery, but no 
changes at postpartum were observed for the remaining antibod-
ies. In accordance, previous manuscripts have shown increases 
(55–57), no changes (58) and even decreases (59) in Pf and Pv 
antibody levels at postpartum compared to pregnancy, depending 
on study site and antigen. We also believe the timing of sampling 
after delivery could help explain some of the differences observed 
in the literature. Therefore, there is a need to harmonize immune-
epidemiological studies at postpartum to elucidate whether this is 
a period of immunological recovery or susceptibility. 
Although many of the antigens studied here are vaccine 
candidates, no protective association with future Plasmodium 
infection was found. On the contrary, a positive (non-protective) 
association was found with some antibody levels at recruitment 
and future infection, as previously described in a cohort in 
Thailand (12), suggesting that these antibodies are markers of 
exposure in our cohort. Actually, this was not entirely surprising 
as women are known to be susceptible to Pf infections during 
pregnancy despite having acquired immunity (19). In addition, 
studies showing protection for Pf antigens such as PfMSP119 or 
PfAMA1 have been conducted mainly in children/teenagers (60), 
and we and others have previously reported lack of protective 
associations in adults (51, 61–64). Moreover, it has already been 
reported in a number of studies that one of the strongest risk fac-
tors for falciparum malaria is having had episodes in the past (65, 
66). However, it is not clear whether anti-Pv antibodies confer 
protection for Pv malaria during pregnancy. Even though our 
data suggest that they do not, a limitation in this study, which 
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TaBle 6 | cytokine, chemokine, and growth factor concentrations in 
peripheral blood mononuclear cell supernatants.
DBP PvMsP119
U i p adj-p U i P adj-p
EGF 40 40 0.983 1 32 40 0.263 1
CCL11 13 3 0.221 1 3 3 0.555 1
FGF-basic 18 17 0.812 1 15 17 0.945 1
G-CSF 131 183 0.033 0.99 129 157 0.212 1
GM-CSF 38 38 0.733 1 38 38 0.151 1
HGF 245 162 0.123 1 265 193 0.381 1
IFN-α 238 208 0.523 1 208 226 0.407 1
IFN-γ 13 13 0.772 1 13 13 0.481 1
IL-10 56 99 0.283 1 33 44 0.332 1
IL-12 71 62 0.610 1 52 38 0.963 1
IL-13 74 73 0.696 1 67 74 0.549 1
IL-15 147 152 0.801 1 282 127 0.709 1
IL-17 125 42 0.046 1 125 125 0.960 1
IL-1β 77 72 0.812 1 50 63 0.311 1
IL-1Ra 1,731 1,503 0.340 1 1,521 1,478 0.945 1
IL-2 11 9 0.137 1 12 8 0.213 1
IL-2R 209 235 0.665 1 100 134 0.140 1
IL-4 14 42 0.060 1 20 24 0.870 1
IL-5 8 8 0.234 1 8 8 0.739 1
IL-6 1,513 2,701 0.129 1 907 1,623 0.102 1
IL-7 75 76 0.182 1 75 75 0.979 1
CXCL-8 64,000 64,000 0.720 1 64,000 64,000 0.283 1
IP10 7 6 0.495 1 6 6 0.596 1
CCL2 18,010 16,677 0.811 1 15,351 19,126 0.627 1
CXCL9 113 113 0.320 1 113 113 0.832 1
CCL3 2,289 2,308 0.845 1 516 1,081 0.269 1
CCL4 1,840 1,881 0.633 1 978 1,168 0.214 1
CCL5 139 162 0.948 1 70 52 0.417 1
TNF 89 77 0.845 1 34 53 0.056 1
VEGF 90 111 0.335 1 63 94 0.134 1
Median concentration (pg/mL) values for each cytokine, chemokine, and growth factor 
in supernatants from the infected (I, N = 28) and uninfected (U, N = 18) groups after 
stimulation with DBP peptides or PvMSP119. Reference values for medium and anti-
CD3 stimulation have been published previously (24). p corresponds to Mann–Whitney 
test. Highlighted in bold if p < 0.05. adj-p corresponds to the p-value adjusted for 
multiple comparisons using the Bonferroni method.
G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage 
colony-stimulating factor; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor; IP, 
IFN-γ-inducible protein; EGF, epidermal growth factor; FGF, fibroblast growth factor; 
HGF, hepatocyte growth factor; VEGF, vascular endothelial growth factor.
is an unsolved and highly complex issue in most field studies, 
was how to control the heterogeneity of previous exposure at the 
individual level and thus distinguish when antibodies are markers 
of exposure or protection.
In this line, we observed no association between anti-VAR2CSA 
responses and gravidity or protection against future Pf infection, 
in contrast to many studies in Africa but similarly to findings in 
Thailand (12). In fact, it has been postulated that multigravidae 
are likely to be serologically equivalent to primigravidae in areas 
of low transmission (67). It is also possible that we could not find a 
protective association with infection because (a) active detection 
was only performed at recruitment and delivery, so we might have 
missed asymptomatic infections during pregnancy; (b) most of 
the infections were submicroscopic for which naturally acquired 
immunity does not confer sterile protection. Importantly, sub-
microscopic Pf infections are still associated with poor outcomes 
like anemia and low BW even if they are asymptomatic [(68) and 
unpublished results]. In this sense, we found a positive protective 
association between anti-PfDBL3x IgG levels at recruitment and 
BW, as previously shown in a few studies (23, 67).
Interestingly, we report for the first time to our knowledge 
a positive association between the levels of binding-inhibitory 
anti-PvDBP antibodies at recruitment and BW. This result was 
somehow unexpected as we did not observe protection against 
future Pv infection, neither did we observe an association between 
Pv infection and low BW (LBW, <2,500 g) in the main Pregvax 
cohort (unpublished results). High functional (inhibitory) 
anti-PvDBP levels have been associated with delayed time to Pv 
reinfection, reduced risk of Pv, and reduction in Pv parasitemia 
in children from PNG (29). Furthermore, levels of functional 
but not general anti-PvDBP antibodies have been associated 
with protection against clinical malaria in adults in Brazil (30). 
It seems that protection against infection is only observed in 
children or for symptomatic malaria, which could explain why 
we did not observe an association with infection in our cohort. 
Regardless, our results suggest that functional anti-PvDBP might 
protect against deleterious effects of Pv malaria during pregnancy. 
Further studies are needed to confirm this effect.
Regarding cellular immune responses, we observed differ-
ences between infected and non-infected women, but these did 
not seem to be antigen-specific as they were observed also when 
PBMCs were cultured with medium alone. First, we believe that 
baseline immune status and non-specific immune responses 
may have a significant effect on adaptive immune responses 
and morbidity outcomes. Second, as most of the infections in 
our cohort were only detected by PCR, this may imply that high 
parasitemia infections are necessary to boost antigen-specific cel-
lular responses for these two antigens, contrary to the antibody 
responses. In our study, it seems that the pregnancy status favor-
ing a systemic switch to a TH2 response (69) or type-2 immunity 
in general (70) may limit any TH1 parasite-specific protective 
response. In that sense, in the infected group, independently 
of the stimulus, we observed a lower percentage of intracellular 
IFN-γ (only significant for CD8+ T cells) and higher secretion of 
IL-4 (a key TH2 cytokine) and G-CSF, which has been shown to 
induce TH2 polarization in CD4+ T cells (71). Although we found 
differences in the percentage of IFN-γ+ T cells between infected 
and uninfected women, this did not translate into differences 
in the levels of secreted IFN-γ. It is likely that the short incuba-
tion period of the PBMCs after antigen stimulation (12 h until 
secretion was stopped) might have been insufficient for eliciting 
a significant detectable cumulative change of the cytokine in 
culture supernatants. Moreover, other IFN-γ cellular sources like 
NK cells may counteract the T cell effect.
In summary, we have investigated the immune responses to 
several malaria vaccine candidates in a large and geographically 
diverse cohort of pregnant women. Our data suggest that sub-
microscopic infections are enough to boost naturally acquired 
antibody responses to malaria but maybe not T cell responses. 
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We also show that antibody responses to several malaria vaccine 
candidates appear to be boosted in coinfections or in women 
infected with the other Plasmodium species studied, which 
might be interesting in programmatic terms regarding the search 
for a malaria vaccine. Importantly, we report that inhibitory 
anti-PvDBP antibody levels have a positive association with BW, 
suggesting that acquisition of functional anti-PvDBP antibodies 
might confer protection against one poor outcome of malaria in 
pregnancy.
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